Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire; UCL - SSS/IREC/SLUC - Pôle St.-Luc; UCL - (SLuc) Service d'hématologie
    • بيانات النشر:
      Blackwell Pub.
    • الموضوع:
      2020
    • Collection:
      DIAL@USL-B (Université Saint-Louis, Bruxelles)
    • نبذة مختصرة :
      Major therapeutic developments have been achieved in the field of thrombotic and hemorrhagic diseases over the last decade. These include the development and validation of four direct oral anticoagulants (DOACs) indicated for numerous thrombotic disorders, both arterial and venous. 1 Developments also involve new hemostatic agents for hemophilia patients, in particular factor VIII (FVIII) and factor IX (FIX) concentrates with extended halfâ€life (EHL) 2 , 3 and a bispecific antibody mimicking the action of FVIII (emicizumab) [.]
    • ISSN:
      1538-7933
      1538-7836
    • Relation:
      boreal:236440; http://hdl.handle.net/2078.1/236440; info:pmid/32294321; urn:ISSN:1538-7933; urn:EISSN:1538-7836
    • الرقم المعرف:
      10.1111/jth.14845
    • Rights:
      info:eu-repo/semantics/openAccess
    • الرقم المعرف:
      edsbas.4E9222CA